ライフサイエンスコーパス: flucytosine

1 mbination with a low or intermediate dose of flucytosine.

2 ose fluconazole alone or in combination with flucytosine.

3 th fluconazole but no in vivo synergism with flucytosine.

4 atients were treated with amphotericin B and flucytosine.

5 als but not by exposure to amphotericin B or flucytosine.

6 access to amphotericin B; 12% had access to flucytosine.

7 cid and the clinically relevant antifungal 5-flucytosine.

8 41 control participants to IV amphotericin + flucytosine.

9 ative therapy is 2 weeks of fluconazole plus flucytosine.

10 uconazole, itraconazole, amphotericin B, and flucytosine.

11 bated with amphotericin B, itraconazole, and flucytosine.

12 cytosine 50 mg/kg/d, and LAmB 3 mg/kg/d plus flucytosine 100 mg/kg/d all resulted in near-maximal ant

13 cytosine 50 mg/kg/d, and LAmB 3 mg/kg/d plus flucytosine 100 mg/kg/d.

14 cryptococcal meningitis receiving adjunctive flucytosine 100 mg/kg/day.

15 ram of body weight) on day 1 plus 14 days of flucytosine (100 mg per kilogram per day) and fluconazol

16 eoxycholate (1 mg per kilogram per day) plus flucytosine (100 mg per kilogram per day) for 7 days, fo

17 0.7 mg per kilogram per day) with or without flucytosine (100 mg per kilogram per day) for two weeks

18 oxycholate for 4 weeks; (2) amphotericin and flucytosine (100 mg/kg/day) for 2 weeks; and (3) amphote

19 C. krusei to amphotericin B (304 isolates), flucytosine (254 isolates), anidulafungin (121 isolates)

20 photericin B (AmB) (87% vs 24%, p<0.001) and flucytosine (5-FC) (57% vs 16%, p<0.001) when indicated.

21 tive effect of the cytosine deaminase (CD)/5-flucytosine (5-FC) gene therapy approach, in which CD co

22 ts growth of intracellular Burkholderia, and flucytosine (5-FC), an FDA-approved antifungal drug.

23 herapy consists of amphotericin B (AmB) plus flucytosine (5-FC), but 5-FC remains largely unavailable

24 otericin B (AMB) induction therapy (6 with 5-flucytosine [5-FC] for a median of 2 weeks); median dura

25 of LAmB 6 mg/kg/d alone, LAmB 3 mg/kg/d plus flucytosine 50 mg/kg/d, and LAmB 3 mg/kg/d plus flucytos

26 de LAmB 6 mg/kg/d alone, LAmB 3 mg/kg/d plus flucytosine 50 mg/kg/d, and LAmB 3 mg/kg/d plus flucytos

27 to voriconazole (81%), amphotericin B (61%), flucytosine (5FC) (3%), and echinocandins (1%).

28 TA) trial, 2 weeks of fluconazole (FLU) plus flucytosine (5FC) was as effective and less costly than

29 ither FLC monotherapy or in combination with flucytosine (5FC).

30 ketoconazole, 85% for itraconazole, 80% for flucytosine, 77% for terconazole, 66% for miconazole, an

31 NS disease was liposomal amphotericin B with flucytosine (93.8%; mean duration, 31 +/- 13 days).

32 amphotericin B, 99.1% and 97%, respectively; flucytosine, 99.1% and 98.8%, respectively; and voricona

33 c relationships were determined for LAmB and flucytosine administered alone.

34 tion antifungal therapy (amphotericin B plus flucytosine) administered before or after inoculation wa

35 Flucytosine administration at clinically meaningful dosi

36 The in vitro and in vivo activity of flucytosine against P. aeruginosa, combined with its des

37 lerance to fluconazole (FLC), micafungin, 5- flucytosine and amphotericin B compared to younger (0-3

38 ble access to essential medicines, including flucytosine and amphotericin B, in LMICs is paramount an

39 B and C. krusei, itraconazole and C. krusei, flucytosine and C. parapsilosis, fluconazole and C. para

40 mphotericin B in combination with 14 days of flucytosine and fluconazole (AMBITION-cm regimen) for in

41 -dose liposomal amphotericin B combined with flucytosine and fluconazole was noninferior to the WHO-r

42 s reported identical Etest MICs, the MICs of flucytosine and fluconazole when tested against C. kruse

43 liposomal amphotericin B, combined with oral flucytosine and fluconazole.

44 e 202 patients receiving amphotericin B plus flucytosine and in 51 percent of the 179 receiving ampho

45 Flucytosine and itraconazole are the only antifungal age

46 r flucytosine, and VGIII MICs were lower for flucytosine and itraconazole.

47 The VITEK 2 system reliably detected flucytosine and voriconazole resistance among Candida sp

48 ments between the VITEK 2 system and BMD for flucytosine and voriconazole were 98.1 to 98.6% at the 2

49 etermination of MICs of amphotericin B and 5-flucytosine and warrants further evaluation.

50 n monotherapy, $75 121 for amphotericin plus flucytosine, and $44 605 for amphotericin plus fluconazo

51 e, isavuconazole, ketoconazole, terbinafine, flucytosine, and amphotericin B.

52 Resistance to amphotericin B, flucytosine, and fluconazole was < or = 1% overall.

53 tifungal drugs: amphotericin B deoxycholate, flucytosine, and fluconazole.

54 isolates were resistant to amphotericin B, 5-flucytosine, and fluconazole.

55 is in LMICs is 1 week of amphotericin B plus flucytosine, and the alternative therapy is 2 weeks of f

56 oformans MICs, C. gattii MICs were lower for flucytosine, and VGIII MICs were lower for flucytosine a

57 ates of Candida spp. against amphotericin B, flucytosine, and voriconazole.

58 of amphotericin-based therapy combined with flucytosine are currently the preferred options for indu

59 uconazole and the impact of combination with flucytosine are not known.

60 ment guidelines recommend amphotericin B and flucytosine as first-line induction treatment for crypto

61 Amphotericin B plus flucytosine, as compared with amphotericin B alone, is a

62 than historical controls in Uganda receiving flucytosine at 100 mg/kg/day of 0.41 log10 CFU/mL/day (P

63 Participants received 10 days of flucytosine at 60 mg/kg/day in three divided doses, comb

64 Patients in group 2 concurrently received flucytosine at a dose of 100 mg per kilogram per day for

65 combination therapy with amphotericin B and flucytosine, but standard flucytosine dosing of 100 mg/k

66 traconazole (C. krusei and C. parapsilosis), flucytosine (C. parapsilosis), and fluconazole (C. parap

67 solates for amphotericin B, fluconazole, and flucytosine (Candida parapsilosis ATCC 22019 and Candida

68 to generic drug manufacturer monopolization, flucytosine currently costs approximately $2000 per day

69 he 106 isolates tested, amphotericin B and 5-flucytosine demonstrated the highest agreement in MICs b

70 Reduced flucytosine dose of 60 mg/kg/day for 10 days demonstrate

71 The FLOOR trial investigated whether lower flucytosine dosing maintained therapeutic efficacy and r

72 amphotericin B and flucytosine, but standard flucytosine dosing of 100 mg/kg/day is associated with h

73 In a multivariate analysis, the addition of flucytosine during the initial two weeks and treatment w

74 cies-specific ECVs for amphotericin B (AMB), flucytosine (FC) and itraconazole (ITR) for eight Candid

75 ole (I), voriconazole (V), posaconazole (P), flucytosine (FC), caspofungin (C), and amphotericin B (A

76 tes to the antifungal agents amphotericin B, flucytosine, fluconazole, and itraconazole was determine

77 systemic antifungal agents (amphotericin B, flucytosine, fluconazole, and itraconazole).

78 ungal agents tested included amphotericin B, flucytosine, fluconazole, itraconazole, posaconazole, ra

79 determined for anidulafungin, caspofungin, 5-flucytosine, fluconazole, itraconazole, posaconazole, vo

80 agents for in vitro testing (amphotericin B, flucytosine, fluconazole, ketoconazole, itraconazole, cl

81 ined the susceptibilities to amphotericin B, flucytosine, fluconazole, posaconazole, ravuconazole, vo

82 The MICs of amphotericin B, flucytosine, fluconazole, voriconazole, posaconazole, an

83 intravenous amphotericin B, with or without flucytosine, followed by therapy with fluconazole.

84 otericin B, fluconazole, itraconazole, and 5-flucytosine for all 106 isolates.

85 h 24-h MICs (92 to 100%) with the azoles and flucytosine for all the species tested, with the excepti

86 recommend treatment with amphotericin B plus flucytosine for at least 2 weeks, followed by fluconazol

87 photericin B deoxycholate when combined with flucytosine for the treatment of HIV-associated cryptoco

88 f 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency viru

89 sulfoxide as the solvent for fluconazole and flucytosine impacted the in vitro potency.

90 uconazole with 1 week of amphotericin B plus flucytosine in AMBITION-cm, hazard ratios were 0.50 (95%

91 trials on the anti-P. aeruginosa efficacy of flucytosine in humans.

92 ivity of daily liposomal amphotericin B with flucytosine induction regimens for cryptococcal meningit

93 We found that the antimycotic agent flucytosine inhibits the expression of the iron-starvati

94 tosine deaminase, which converts a prodrug 5-flucytosine into a cytotoxic 5-fluorouracil.

95 Flucytosine is a key treatment but is expensive and rare

96 , the use of higher-dose amphotericin B plus flucytosine is associated with an increased rate of cere

97 Flucytosine is currently cost-effective in the United St

98 ericin B (LAmB) alone or in combination with flucytosine is not known.

99 Combination therapy with amphotericin and flucytosine is the most attractive treatment strategy fo

100 However, flucytosine is unavailable in Africa and most of Asia, a

101 gal therapy (amphotericin B deoxycholate and flucytosine) is the recommended treatment for cryptococc

102 y Etest against amphotericin B, fluconazole, flucytosine, itraconazole, and ketoconazole in each of f

103 The MICs of amphotericin B, fluconazole, flucytosine, itraconazole, and ketoconazole were determi

104 MICs of amphotericin B, fluconazole, flucytosine, itraconazole, and ketoconazole were determi

105 ential and categorical agreement between the flucytosine MIC readings at 48 and 24 h for Candida spec

106 ts < or =1 year old were more susceptible to flucytosine (MIC at which 90% of isolates are inhibited

107 Amphotericin B (MIC(50),1 microg/ml) and flucytosine (MIC(50), 0.12 microg/ml) are both active in

108 to caspofungin (MIC(90), 0.06 microg/ml) and flucytosine (MIC(90), 0.12 microg/ml) and exhibited vari

109 ceptible [S] at a MIC of </=1 microg/ml) and flucytosine (MIC(90), 0.12 microg/ml; 99.2% S) were the

110 s were inhibited [MIC(90)], 4 microg/ml) and flucytosine (MIC(90), 16 microg/ml) were noted, whereas

111 3% of C. albicans isolates were resistant to flucytosine (MIC, > or = 32 microg/ml), compared to < 1%

112 Susceptibility to flucytosine (MIC, < or = 4 microg/ml) increased from 34%

113 Susceptibility to flucytosine (MIC, < or = 4 microg/ml) ranged from 35% in

114 Comparison of the flucytosine MICs obtained with RPMI 1640 medium revealed

115 oriconazole and to have significantly higher flucytosine MICs than C. glabrata strains.

116 cin B deoxycholate at 0.7-1.0 mg/kg/day with flucytosine (n = 404) as induction therapy.

117 liposomal amphotericin B at 3 mg/kg/day with flucytosine (n = 94) or amphotericin B deoxycholate at 0

118 mphotericin B, liposomal amphotericin B, and flucytosine, need to be much more widely available.

119 with induction therapy of amphotericin B and flucytosine occurred in 76.4% of patients.

120 trolled trial to determine whether combining flucytosine or high-dose fluconazole with high-dose amph

121 (amphotericin monotherapy, amphotericin with flucytosine, or amphotericin with fluconazole).

122 r antifungal agents, such as amphotericin B, flucytosine, or itraconazole.

123 ose liposomal amphotericin B plus 14 days of flucytosine plus fluconazole with 1 week of amphotericin

124 Both LAmB and flucytosine produced a dose-dependent reduction in funga

125 no ECV determined; terbinafine, 0.25 ug/mL; flucytosine, rejected; and amphotericin, 8 ug/mL.

126 ysis was performed to determine the value of flucytosine relative to alternative regimens.

127 fluconazole-resistant isolates (3%) and one flucytosine-resistant isolate (1%) as susceptible, repre

128 l, 1-week (short course) amphotericin B plus flucytosine resulted in a 10-week mortality of 24% (95%

129 CI -16 to 32) and 2 weeks of fluconazole and flucytosine resulted in a 10-week mortality of 35% (95%

130 ble to the majority of antifungals, and only flucytosine showed poor antifungal activity.

131 The flucytosine susceptibility results indicated that strain

132 onazole-susceptible isolates (3%), and three flucytosine-susceptible isolates (4%), representing 12 m

133 among patients receiving amphotericin B and flucytosine than among those receiving amphotericin B al

134 mphotericin through 2 weeks with 100 mg/kg/d flucytosine, then 1.2 g/d LNC amphotericin through 6 wee

135 41) received 7 days of IV amphotericin with flucytosine, then 7 days of fluconazole 1200 mg/d.

136 and insufficiently coordinated distribution; flucytosine through cost and scarcity of registration; a

137 The daily flucytosine treatment cost in the United Kingdom is appr

138 per day in the United States, with a 2-week flucytosine treatment course costing approximately $28 0

139 The ICER of amphotericin plus flucytosine was $23 842 per quality-adjusted life-year.

140 The EFA of reduced dose flucytosine was 0.28 log10 CFU/mL/day (95% CI, 0.20 to 0

141 Amphotericin B plus flucytosine was associated with significantly increased

142 One-week amphotericin B plus flucytosine was associated with the lowest 1 year mortal

143 Resistance to fluconazole and flucytosine was observed infrequently (3.7% and 3.0%); 1

144 ven with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organiz

145 nazole in combination with intermediate-dose flucytosine were effective in reducing CSF cryptococcal

146 d 80 participants to oral LNC amphotericin + flucytosine with (n = 40) and without (n = 40) 2 IV load